Top Pharmaceutical Stocks for 2013: Crown Marketing Inc., Pfizer Inc., Merck & Co. Inc., and Eli Lilly and Company

Wed Jan 16, 2013 9:01am EST

* Reuters is not responsible for the content in this press release.

Top Pharmaceutical Stocks for 2013: Crown Marketing Inc., Pfizer Inc., Merck & Co. Inc.,
and Eli Lilly and Company

NEW YORK, January 16, 2013 /PRNewswire/ --

    PremierEquityReports.com [http://www.premierequityreports.com ] provides investors
with quality research and analysis on U.S. equities on the move and today issues a
report on the top pharmaceutical companies for 2013: Crown Marketing Inc. (OTCBB :
CWNM), Pfizer Inc. (NYSE : PFE), Merck & Co. Inc. (NYSE : MRK), and Eli Lilly and
Company (NYSE : LLY).  

    Crown Marketing Inc. (OTCBB : CWNM) has recently patented a controlled drug delivery
technology that aims not only to improve the safety and pharmacokinetics of
controlled-release medication, but also to streamline the manufacturing process for
existing facilities without significantly increasing costs. Crown Marketing is seeking
to change the time-release process entirely, providing a true 24-hour sustained-release
delivery system.  

    Crown Marketing has also announced that the smart drug delivery revolution has
officially arrived.  

    Read the entire press release issued by Crown Marketing Inc. (OTCBB : CWNM) here:
http://finance.yahoo.com/news/crown-marketing-announces-smart-drug-175924186.html  

    Pfizer Inc. (NYSE : PFE) has been the buzz of Wall Street with rumors circulating
that the company will split its drug division in two. President Geno Germano said,
"...probably going to evolve to two, where there's the innovative business and the value
business," in a January 8th interview. This news excites analysts because a split would
make sense and would turn eyes away from its pipeline and base business to financial
engineering.  

    TheStreet.com, website of infamous stock picker Jim Cramer, has reiterated a buy
rating on Pfizer with a rating score of A-.  

    Read the entire press release issued by TheStreet.com about Pfizer Inc. (NYSE : PFE)
here:
http://www.thestreet.com/story/11813258/1/pfizer-inc-stock-buy-recommendation-reiterated-pfe.html?puc=yahoo&cm_ven=YAHOO
 

    Merck & Co. Inc. (NYSE : MRK) recently announced that it is taking its cholesterol
management drug, Tredaptive, off the market. The decision was based on preliminary data
from a long term safety study.  

    Read the entire press release about Merck & Co. Inc. (NYSE : MRK) here:
http://finance.yahoo.com/news/merck-stop-selling-tredaptive-231852003.html  

    Sam Isaly's Orbimed Advisors, a large health care fund investing in healthcare
companies, reported a position of 4.6 million shares in Merck, a 33% increase from three
months earlier.  

    Eli Lilly and Company's (NYSE : LLY) brain-plaque diagnostic was approved for use in
adult patients by European health regulators on Tuesday. Their imaging agent is used to
detect brain plaques that are considered a possible cause of Alzheimer's disease. This
radioactive diagnostic called Amyvid, was approved for use in the United States last
April. The brain plaques were previously only detectable through autopsy.  

    Read the entire press release about Eli Lilly and Company (NYSE : LLY) here:
http://www.reuters.com/article/2013/01/15/lilly-diagnostic-idUSL2N0AKJRH20130115?feedType=RSS&feedName=rbssHealthcareNews&rpc=43
 

    Sign up to receive detailed reports and stock picks at
http://www.PremierEquityReports.com. For real-time trade updates, follow our award
winning hedge fund trader on Twitter @StockBrainiac. Premier Equity Reports also offers
a FREE text message alert service to ensure that you receive all alerts. Simply text
"reports" to 63566.  

    Premier Equity Reports is the U.S. leader in equity reports, offering quality
reports to investors looking for the most undervalued companies in the market. Premier
Equity Reports provides its subscribers with timely information and exclusive analysis
on U.S. companies with substantial upside potential. Premier Equity Reports is the #1
free financial newsletter in the industry. Sign up now and see why thousands have joined
already.  

    Disclosure: PremierEquityReports.com is not a registered investment advisor and
nothing contained in any materials should be construed as a recommendation to buy or
sell securities. Investors should always conduct their own due diligence with any
potential investment. Premier Equity Reports is a wholly owned entity of Equities
Awareness Group LLC. Equities Awareness Group LLC has been compensated one hundred
thousand dollars for marketing awareness on Crown Marketing Inc. Please read our report
and visit our website, for complete risks and disclosures.  

        
        Contact Information:
        Equities Awareness Group LLC
        Michael Perinotti
        mike@equitiesag.com
        http://www.EquitiesAG.com
        +1-201-917-5934
        Third Party Publishing Provider: FNNewswire, a FN Media Group, LLC Company.


Equities Awareness Group LLC
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.